{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:48:51Z","timestamp":1791236931669,"version":"4.1.0"},"reference-count":38,"publisher":"Pharmaceutical Society of Japan","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1248\/bpb.b16-00987","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T22:06:12Z","timestamp":1498860372000},"page":"992-1001","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacological Profiles of a Highly Potent and Long-Acting Angiotensin II Receptor Antagonist, Fimasartan, in Rats and Dogs after Oral Administration"],"prefix":"10.1248","volume":"40","author":[{"given":"Soo Heui","family":"Paik","sequence":"first","affiliation":[{"name":"Central Research Institute, Boryung Pharm. Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Ha","family":"Chi","sequence":"additional","affiliation":[{"name":"Central Research Institute, Boryung Pharm. Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Han","family":"Lee","sequence":"additional","affiliation":[{"name":"Central Research Institute, Boryung Pharm. Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Soo","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biochemistry College of Pharmacy, Kyung Hee University"},{"name":"Life and Nanopharmaceutical Science, College of Pharmacy, Kyung Hee University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Tae","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biochemistry College of Pharmacy, Kyung Hee University"},{"name":"Life and Nanopharmaceutical Science, College of Pharmacy, Kyung Hee University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) He J, Whelton PK. Epidemiology and prevention of hypertension. <i>Med. Clin. North Am.<\/i>, <b>81<\/b>, 1077\u20131097 (1997).","DOI":"10.1016\/S0025-7125(05)70568-X"},{"key":"2","unstructured":"2) James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA<\/i>, <b>311<\/b>, 507\u2013520 (2014)."},{"key":"3","unstructured":"3) Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, B\u00f6hm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Ryd\u00e9n L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>Eur. Heart J.<\/i>, <b>34<\/b>, 2159\u20132219 (2013)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil <i>versus<\/i> olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. <i>Hypertension<\/i>, <b>57<\/b>, 413\u2013420 (2011).","DOI":"10.1161\/HYPERTENSIONAHA.110.163402"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Michel MC, Foster C, Brunner HR, Liu L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. <i>Pharmacol. Rev.<\/i>, <b>65<\/b>, 809\u2013848 (2013).","DOI":"10.1124\/pr.112.007278"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. <i>Am. J. Hypertens.<\/i>, <b>13<\/b>, 18S\u201324S (2000).","DOI":"10.1016\/S0895-7061(99)00250-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Burnier M, Brunner HR. Angiotensin II receptor antagonists. <i>Lancet<\/i>, <b>355<\/b>, 637\u2013645 (2000).","DOI":"10.1016\/S0140-6736(99)10365-9"},{"key":"8","unstructured":"8) Park JB, Sung KC, Kang SM, Cho EJ. Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study. <i>Am. J. Cardiovasc. Drugs<\/i>, <b>13<\/b>, 47\u201356 (2013)."},{"key":"9","unstructured":"9) Lee SE, Kim YJ, Lee HY, Yang HM, Park CG, Kim JJ, Kim SK, Rhee MY, Oh BH, Investigators. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50\/100\u2009mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. <i>Clin. Ther.<\/i>, <b>34<\/b>, 552\u2013568, 568.e1\u2013568.e9 (2012)."},{"key":"10","unstructured":"10) Gu N, Kim BH, Lim KS, Kim SE, Nam WS, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial. <i>Clin. Ther.<\/i>, <b>34<\/b>, 1592\u20131600 (2012)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Jeon H, Lim KS, Shin KH, Kim J, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. Assessment of the drug-drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers. <i>J. Cardiovasc. Pharmacol.<\/i>, <b>59<\/b>, 84\u201391 (2012).","DOI":"10.1097\/FJC.0b013e318237389e"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Yi S, Kim TE, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. <i>J. Cardiovasc. Pharmacol.<\/i>, <b>57<\/b>, 682\u2013689 (2011).","DOI":"10.1097\/FJC.0b013e31821795d0"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Lim HJ, Lee SK, Lim DY. Influence of Fimasartan (a Novel AT(1) Receptor Blocker) on Catecholamine Release in the Adrenal Medulla of Spontaneously Hypertensive Rats. <i>Korean J. Physiol. Pharmacol.<\/i>, <b>17<\/b>, 99\u2013109 (2013).","DOI":"10.4196\/kjpp.2013.17.1.99"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Han J, Park SJ, Thu VT, Lee SR, Long T, Kim HK, Kim N, Park SW, Jeon ES, Kim EJ, Yoon CH, Cho GY, Choi DJ. Effects of the novel angiotensin II receptor type I antagonist, fimasartan on myocardial ischemia\/reperfusion injury. <i>Int. J. Cardiol.<\/i>, <b>168<\/b>, 2851\u20132859 (2013).","DOI":"10.1016\/j.ijcard.2013.03.151"},{"key":"15","unstructured":"15) Lee JY, Lee CW, Kim WJ, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH, Son WC, Jung S, Park SW, Park SJ. Antiatherosclerotic effects of the novel angiotensin receptor antagonist fimasartan on plaque progression and stability in a rabbit model: a double-blind placebo-controlled trial. <i>J. Cardiovasc. Pharmacol.<\/i>, <b>62<\/b>, 229\u2013236 (2013)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Ryu S, Shin JS, Cho YW, Kim HK, Paik SH, Lee JH, Chi YH, Kim JH, Kim JH, Lee KT. Fimasartan, anti-hypertension drug, suppressed inducible nitric oxide synthase expressions <i>via<\/i> nuclear factor-kappa B and activator protein-1 inactivation. <i>Biol. Pharm. Bull.<\/i>, <b>36<\/b>, 467\u2013474 (2013).","DOI":"10.1248\/bpb.b12-00859"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Chi YH, Lee JH, Kim JH, Tan HK, Kim SL, Lee JY, Rim HK, Paik SH, Lee KT. Pharmacological characterization of BR-A-657, a highly potent nonpeptide angiotensin II receptor antagonist. <i>Biol. Pharm. Bull.<\/i>, <b>36<\/b>, 1208\u20131215 (2013).","DOI":"10.1248\/bpb.b12-00966"},{"key":"18","unstructured":"18) OTTO-BRUG A. Final report. <i>In vitro<\/i> pharmacology: Study part 1. Binding study of several compounds at human AT1 and AT2 receptors. <i>Cerep<\/i>, 7\u201312 (2012)."},{"key":"19","unstructured":"19) OTTO-BRUG A. Final report. <i>In vitro<\/i> pharmacology: Study part 2. Reversibility of custoumer compounds binding at the human AT1 receptor without labeling of the compounds. <i>Cerep<\/i>, 6\u201314 (2012)."},{"key":"20","unstructured":"20) OTTO-BRUG A. Final report. <i>In vitro<\/i> pharmacology. Study part 3: 5 customer compounds <i>k<\/i><sub>on<\/sub>\/<i>k<\/i><sub>off<\/sub> rates estimation in the AT1 receptor binding assay without labeing of the compound. <i>Cerep<\/i>, 7\u201317 (2013)."},{"key":"21","unstructured":"21) Wong PC, Price WA Jr, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PB. Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists: X. <i>Hypertension<\/i>, <b>15<\/b>, 459\u2013468 (1990)."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Inada Y, Wada T, Shibouta Y, Ojima M, Sanada M, Ohtsuki K, Itoh K, Kubo K, Kohara Y, Naka T, Nishikawa K. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (\u00b1)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2\u2032-(1<i>H<\/i>-tetrazol-5-yl)biphenyl-4-yl]methyl]-1<i>H<\/i>- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>268<\/b>, 1540\u20131547 (1993).","DOI":"10.1016\/S0022-3565(25)38647-7"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Tamura K, Okuhira M, Amano H, Inokuma K, Hirata T, Mikoshiba I, Hashimoto K. Pharmacologic profiles of KRH-593, a novel nonpeptide angiotensin II-receptor antagonist. <i>J. Cardiovasc. Pharmacol.<\/i>, <b>30<\/b>, 607\u2013615 (1997).","DOI":"10.1097\/00005344-199711000-00011"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Henry R, Casto R, Printz MP. Diurnal cardiovascular patterns in spontaneously hypertensive and Wistar-Kyoto rats. <i>Hypertension<\/i>, <b>16<\/b>, 422\u2013428 (1990).","DOI":"10.1161\/01.HYP.16.4.422"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Wienen W, Hauel N, Van Meel JC, Narr B, Ries U, Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. <i>Br. J. Pharmacol.<\/i>, <b>110<\/b>, 245\u2013252 (1993).","DOI":"10.1111\/j.1476-5381.1993.tb13800.x"},{"key":"26","unstructured":"26) Criscione L, de Gasparo M, Buhlmayer P, Whitebread S, Ramjoue HP, Wood J. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. <i>Br. J. Pharmacol.<\/i>, <b>110<\/b>, 761\u2013771 (1993)."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Noda M, Shibouta Y, Inada Y, Ojima M, Wada T, Sanada T, Kubo K, Kohara Y, Naka T, Nishikawa K. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. <i>Biochem. Pharmacol.<\/i>, <b>46<\/b>, 311\u2013318 (1993).","DOI":"10.1016\/0006-2952(93)90420-2"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Chiu AT, McCall DE, Price WA, Wong PC, Carini DJ, Duncia JV, Wexler RR, Yoo SE, Johnson AL, Timmermans PB. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>252<\/b>, 711\u2013718 (1990).","DOI":"10.1016\/S0022-3565(25)19981-3"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Choi MJ, Kwon GH, Han NS, Yoo BW, Kim JH, Paik SH, Chi YH, Lee K-T, Lee JY. Development of 3D-QSAR CoMSIA models for 5-(biphenyl-2-yl)-1<i>H<\/i>-tetrazole derivatives as angiotensin II receptor type 1 (AT<sub>1<\/sub>) antagonists. <i>Bioorg. Med. Chem. Lett.<\/i>, <b>23<\/b>, 4540\u20134546 (2013).","DOI":"10.1016\/j.bmcl.2013.06.041"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Unger T. Pharmacology of AT1-receptor blockers. <i>Blood Press. Suppl.<\/i>, <b>10<\/b>, 5\u201310 (2001).","DOI":"10.1080\/08037050152518302"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Morsing P, Adler G, Brandt-Eliasson U, Karp L, Ohlson K, Renberg L, Sj\u00f6quist PO, Abrahamsson T. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. <i>Hypertension<\/i>, <b>33<\/b>, 1406\u20131413 (1999).","DOI":"10.1161\/01.HYP.33.6.1406"},{"key":"32","unstructured":"32) Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: <i>in vitro<\/i> evidence for insurmountable antagonism and inverse agonism. <i>Mol. Cell. Endocrinol.<\/i>, <b>302<\/b>, 237\u2013243 (2009)."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Ojima M, Igata H, Tanaka M, Sakamoto H, Kuroita T, Kohara Y, Kubo K, Fuse H, Imura Y, Kusumoto K, Nagaya H. <i>In vitro<\/i> antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>336<\/b>, 801\u2013808 (2011).","DOI":"10.1124\/jpet.110.176636"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Vanderheyden PM, Fierens FL, Vauquelin G. Angiotensin II type 1 receptor antagonists. Why do some of them produce insurmountable inhibition? <i>Biochem. Pharmacol.<\/i>, <b>60<\/b>, 1557\u20131563 (2000).","DOI":"10.1016\/S0006-2952(00)00388-9"},{"key":"35","unstructured":"35) Vanderheyden P, Fierens F, Vauquelin G, Verheijen I. The <i>in vitro<\/i> binding properties of non-peptide AT1 receptor antagonists. <i>J. Clin. Basic Cardiol.<\/i>, <b>5<\/b>, 75\u201382 (2002)."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Hilditch A, Hunt AA, Gardner CJ, Twissell DJ, Polley J, Travers A, Drew GM, Middlemiss D, Ross BC, Robertson MJ. Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist. <i>Br. J. Pharmacol.<\/i>, <b>111<\/b>, 137\u2013144 (1994).","DOI":"10.1111\/j.1476-5381.1994.tb14035.x"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Bhardwaj G. How the antihypertensive losartan was discovered. <i>Expert Opin. Drug Discov.<\/i>, <b>1<\/b>, 609\u2013618 (2006).","DOI":"10.1517\/17460441.1.6.609"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Mizuno K, Niimura S, Tani M, Saito I, Sanada H, Takahashi M, Okazaki K, Yamaguchi M, Fukuchi S. Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats. <i>Life Sci.<\/i>, <b>51<\/b>, PL183\u2013PL187 (1992).","DOI":"10.1016\/0024-3205(92)90627-2"}],"container-title":["Biological &amp; Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/7\/40_b16-00987\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T20:18:40Z","timestamp":1750450720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/7\/40_b16-00987\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b16-00987","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}